Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Jul 3:2024.06.12.24308839.
doi: 10.1101/2024.06.12.24308839.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology

Suzanne E Schindler, Kellen K Petersen, Benjamin Saef, Duygu Tosun, Leslie M Shaw, Henrik Zetterberg, Jeffrey L Dage, Kyle Ferber, Gallen Triana-Baltzer, Lei Du-Cuny, Yan Li, Janaky Coomaraswamy, Michael Baratta, Yulia Mordashova, Ziad S Saad, David L Raunig, Nicholas J Ashton, Emily A Meyers, Carrie E Rubel, Erin G Rosenbaugh, Anthony W Bannon, William Z Potter

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology

Suzanne E Schindler et al. medRxiv. .

Update in

  • Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.
    Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ; Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team. Schindler SE, et al. Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12. Alzheimers Dement. 2024. PMID: 39394841 Free PMC article.

Abstract

Introduction: Blood tests have the potential to improve the accuracy of Alzheimer disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.

Methods: Plasma samples from the Alzheimers Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.

Results: Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.

Discussion: This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.

PubMed Disclaimer

Publication types

LinkOut - more resources